IDPL to pharma capital : who built Hyderabad’s drug industry

 

THE RECORD BEHIND THE BRAND

IDPL to pharma capital: who built Hyderabad’s drug industry—and what the numbers leave out

A public-sector plant helped seed a private manufacturing network. Today’s export and production claims confirm a major cluster—but the statistics are not interchangeable, and the industrial record carries environmental questions.

By Murthy ASR  |  Biz Masala  |  11 October 2026

From public-sector manufacturing to a modern life-sciences cluster: a conceptual illustration, not an archival photograph or a specific Hyderabad facility.

The phrase “pharma capital” is repeated in investment pitches, policy documents and corporate histories. Telangana’s 2026–30 life-sciences policy says the state contributes 40 per cent of India’s pharmaceutical production. A recent PIB factsheet gives a different formulation: about one-third of national production, half of bulk-drug exports and one-fifth of total pharma exports. Both describe scale; neither, on its own, explains the measurement behind the headline. [1][2]

The paper trail points to a more interesting story than a slogan. Hyderabad’s pharmaceutical base was built over decades: first through a central public-sector plant and the technical skills it concentrated, then through private entrepreneurs, export markets, research institutions and deliberate cluster-building. But the companies that grew from this ecosystem do not all make their products in Hyderabad, and the city’s industrial success has also left a contested environmental record.

A state boundary changed; the industrial story did not

IDPL was incorporated in 1961 to support self-reliance in essential drugs. Its Hyderabad plant was commissioned in 1967. At the time, Hyderabad sat in Andhra Pradesh; since the 2014 state division, it is Telangana’s capital. The distinction matters: today’s Telangana operates the Hyderabad ecosystem, while its early public investment and several formative company histories belong to undivided Andhra Pradesh. [3][4]

 

How the manufacturing base reproduced itself

In a 2010 interview, Dr K. Anji Reddy recalled learning bulk-drug skills at IDPL, starting Uniloids in 1976, founding Standard Organics in 1980 and establishing Dr Reddy’s Laboratories in Hyderabad in 1984. He described employees and suppliers becoming entrepreneurs around the company. That is unusually direct evidence of how know-how and supplier relationships circulated—but it is one founder’s retrospective account, not a complete map of every company’s lineage. [4]

“SOL” in that account is Standard Organics. It should not be conflated with SOL Pharmaceuticals, a separate company incorporated in 1983 that later took over Standard Organics’ formulations division. The distinction is small in a timeline, but important in any claim that one firm directly spawned another. [5]

Company / institution	Milestone in the Hyderabad-era story	What the record supports
IDPL	Incorporated 1961; Hyderabad plant commissioned 1967	Public-sector manufacturing and technical base.
Standard Organics (SOL)	Founded by Anji Reddy with partners in 1980, by his account	An entrepreneur’s account of an early private venture; not proof every later firm was its offshoot.
Natco	Pharma division incorporated at Kothur in 1981	Early manufacturing roots in the region; research centre opened later in Hyderabad.
Dr Reddy’s / Neuland	Founded in Hyderabad in 1984; Dr Reddy’s first API unit at Bollaram opened in 1985	Two distinct firms grew from process chemistry and export ambitions.
Aurobindo	Founded in Hyderabad in 1986; first operations at Pondicherry in 1988–89	Origin and headquarters do not mean all production took place locally.
Divi’s / Hetero	Divi’s established in Hyderabad in 1990; Hetero founded in 1993	Later scale-up broadened the regional cluster and product base.

Dates and descriptions drawn from company histories and reported founder testimony. The table tracks origins and milestones, not each company’s current manufacturing footprint. [4][6]

Illustrative API manufacturing scene; no named company or actual plant is shown.

This was not a simple chain in which a government plant turned into a single private conglomerate. The stronger explanation is an ecosystem effect: trained chemists and engineers, process-manufacturing experience, supplier networks, and firms able to compete in active pharmaceutical ingredients (APIs) and generic medicines. A later layer—research institutes and Genome Valley, launched as a knowledge park in 1999—added dedicated R&D and biotech infrastructure. [7]

 

What does “pharma capital” measure?

The clearest comparable public number in the record is state-wise pharmaceutical exports. A written Rajya Sabha reply reported Telangana exports of ₹29,148.9 crore in FY2023–24, against Andhra Pradesh’s ₹11,390.05 crore. Telangana’s figure was about 2.6 times larger; Andhra Pradesh’s reported exports had also nearly doubled from FY2021–22. These data establish Telangana’s export leadership in this series. They do not tell us how much was physically manufactured in Hyderabad city, measure domestic sales, or isolate APIs from finished medicines. [8]

State-wise pharmaceutical export values in the 2024 Rajya Sabha reply. ₹ crore; state attribution is not a direct measure of city-level production. [8]

Three claims, three denominators

Claim in public sources	Metric it appears to describe	What still needs to be disclosed
Telangana policy (2026): 40% of India’s pharma production	Share of national production, but no production series or valuation basis is stated on the policy page.	Value or volume? APIs, formulations, vaccines, or all pharma? Facility location or company address?
PIB factsheet: about one-third of production; 50% of bulk-drug exports; 20% of total pharma exports	A production-share claim plus two export-share claims.	Reference year, source dataset and product classification for each share.
Parliamentary export reply: Telangana ₹29,148.9 crore in FY24	State-wise value of pharmaceutical exports.	Exports attributed to state are not the same thing as total manufacturing output or Hyderabad-only exports.

The state and PIB claims may reflect different dates or definitions; the available public pages do not supply enough detail to reconcile them. They should not be presented as directly conflicting measurements without the underlying methodology. [1][2][8]

The omission is consequential. A “capital” claim can refer to production volume, production value, exports, API capacity, FDA-inspected sites, vaccine output or R&D employment. Those measures overlap, but they are not interchangeable. The company list also needs careful geography: Aurobindo began production in Pondicherry; companies headquartered in Hyderabad now operate plants across multiple Indian states and overseas. The cluster’s influence is real, but corporate address is not a proxy for local output. [6]

 

The externality in the success story

The environmental record is not a footnote. A Central Pollution Control Board action-plan document describes Patancheru–Bollaram as an industrial area with pollution concerns and lists pharmaceutical and other manufacturing units among the sources under scrutiny. Peer-reviewed studies published from 2007 onward measured high pharmaceutical residues in effluent from a treatment plant serving bulk-drug manufacturers and detected drug compounds in nearby water samples. [9][10]

Illustrative wastewater sampling scene, not a photograph of Patancheru–Bollaram or evidence about any named company.

The next claim requires more restraint: the connection between industrial residues, resistant microbes and specific human-health outcomes is scientifically complex. Research has reported antibiotic residues and resistance-related findings, while other studies challenged causal attribution and the choice of comparison sites. A 2025 peer-reviewed analysis documents those disputes and the regulatory history. The responsible conclusion is that pollution is documented and deserves transparent monitoring; direct local disease causation should not be asserted without evidence. [10]

The next phase needs an evidence standard

Telangana’s new policy proposes Green Pharma City with zero-liquid-discharge and centralized waste-management systems, while expanding research, lab and manufacturing infrastructure. These are design commitments and policy plans; their credibility will depend on independent performance data once facilities operate. The test is whether the next industrial expansion can publish water-quality baselines, common-treatment-plant performance, inspection findings, accident data and corrective actions—not only investment and job targets. [1]

The rise of Hyderabad’s pharma sector is not in doubt. The more exact story is that public investment created a technical foothold; private firms and supplier networks converted it into export capability; and later institutions and clusters widened the ecosystem. But the strongest proof of “capital” status is not a slogan. It is transparent, comparable data on what is produced, where it is made, where value is retained—and whether the environmental and safety costs are being controlled.

REPORTING CONCLUSION Hyderabad’s claim to pharma leadership has a strong historical and export record. What remains weak is public comparability: production shares need clear denominators, company origins must be separated from factory locations, and growth claims should sit beside independently measured environmental and worker-safety outcomes.

Sources & reporting notes

[1] Invest Telangana, Next-Gen Life Sciences Policy 2026–2030. Production-share claims and planned cluster infrastructure. Open

[2] Press Information Bureau factsheet, Life Sciences & Pharma Industry. Government summary of production and export shares. Open

[3] Department of Pharmaceuticals, Central Public Sector Enterprises / IDPL history. Open

[4] Dr Reddy’s Laboratories, Hyderabad plant history; and Anji Reddy interview on IDPL, Uniloids and Standard Organics. IDPL plant Founder interview

[5] SOL Pharmaceuticals history, including incorporation and transfer of Standard Organics formulations operations. Open

[6] Company histories: Natco; Dr Reddy’s; Neuland; Aurobindo; Divi’s; Hetero. Natco Dr Reddy’s Neuland Aurobindo Divi’s Hetero

[7] IKP Knowledge Park, Genome Valley / Hyderabad Science Park history. Open

[8] Rajya Sabha Unstarred Question 231, 3 December 2024, state-wise pharma export values for FY2021–22 to FY2023–24. Open

[9] Central Pollution Control Board, Patancheru–Bollaram action-plan implementation note. Open

[10] Larsson et al. (2007), pharmaceutical residues in effluent; and Andersson (2025), review of Hyderabad pollution and AMR evidence and debate. 2007 study 2025 analysis

Desk-research note: This feature is based on public company histories, government policy and parliamentary records, CPCB documentation and published scientific literature. The IDPL-to-entrepreneur pathway is attributed to founder testimony; it is not represented as a complete genealogy of the named firms. Facility-level production, permit-compliance and community-health claims require fresh company, regulator and local-source verification before publication as original field investigation.

Murthy ASR

Biz Masala